Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy

Contraception

Volumn 75, Issue 6 SUPPL., 2007, Pages

  Kadir, Rezan A ^a   Chi, Claudia ^a  

^a DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY   (United Kingdom)

Author keywords

Anticoagulant therapy; Bleeding disorders; Levonorgestrel intrauterine system

Indexed keywords

LEVONORGESTREL; NONSTEROID ANTIINFLAMMATORY AGENT; TRANEXAMIC ACID; WARFARIN;

AMENORRHEA; ANTICOAGULANT THERAPY; BLEEDING DISORDER; DATA ANALYSIS; DYSMENORRHEA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; HYSTERECTOMY; IRON DEFICIENCY ANEMIA; IRREGULAR SPOTTING; MENORRHAGIA; MENSTRUATION; OVARY CYST; QUALITY OF LIFE; REVIEW; VON WILLEBRAND DISEASE;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS, INHERITED; CONTRACEPTIVE AGENTS, FEMALE; DYSMENORRHEA; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENORRHAGIA;

EID: 34248650155     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2007.01.005     Document Type: Review

References (50)

1. Rodeghiero F., Castaman G., and Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69 (1987) 454-459
2. Werner E.J., Broxson E.H., Tucker E.L., Giroux D.S., Shults J., and Abshire T.C. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 123 (1993) 893-898
3. Rodeghiero F., and Castaman G. von Willebrand disease: epidemiology. In: Lee C.A., Berntorp E.E., and KeithHoots W. (Eds). Textbook of Hemophilia (2005), Blackwell Publishing, Oxford, UK 265-271
4. Plug I., Mauser-Bunschoten E.P., Brocker-Vriends A.H.J., et al. Bleeding in carriers of hemophilia. Blood 108 (2006) 52-56
5. Kouides P.A., Phatak P.D., Burkart P., et al. Gynaecological and obstetrical morbidity in women with Type I von Willebrand disease: results of a patient survey. Hemophilia 6 (2000) 643-648
6. Ragni M.V., Bontempo F.A., and Hassett A.C. von Willebrand disease and bleeding in women. Hemophilia 5 (1999) 313-317
7. Foster P.A. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 74 (1995) 784-790
8. Higham J.M., O'Brien P.M., and Shaw R.W. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 97 (1990) 734-739
9. Kadir R.A., Economides D.L., Sabin C.A., Pollard D., and Lee C.A. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Hemophilia 5 (1999) 40-48
10. Kadir R.A., Economides D.L., Sabin C.A., Owens D., and Lee C.A. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 351 (1998) 485-489
11. James A.H. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Hemophilia 11 (2005) 295-307
12. Kirtava A., Drews C., Lally C., Dilley A., and Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in hemophilia treatment centers: a case-control study. Hemophilia 9 (2003) 292-297
13. Barr R.D., Sek J., Horsman J., et al. Health status and health-related quality of life associated with von Willebrand disease. Am J Hematol 73 (2003) 108-114
14. Kadir R.A., Sabin C.A., Pollard D., Lee C.A., and Economides D.L. Quality of life during menstruation in patients with inherited bleeding disorders. Hemophilia 4 (1998) 836-841
15. van Eijkeren M.A., Christiaens G.C.M.L., Haspels A.A., and Sixma J.J. Measured menstrual blood loss in women with a bleeding disorder or using oral anticoagulant therapy. Am J Obstet Gynecol 162 (1990) 1261-1263
16. Tang G.W., and Lo S.S. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception 51 (1995) 231-235
17. Stewart A., Cummins C., Gold L., Jordan R., and Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. BJOG 108 (2001) 74-86
18. Kingman C.E., Kadir R.A., Lee C.A., and Economides D.L. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 111 (2004) 1425-1428
19. Schaedel Z.E., Dolan G., and Powell M. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders. Am J Obstet Gynecol 193 (2005) 1361-1363
20. Pisoni C.N., Cuadrado M.J., Khamashta M.A., and Hunt B.J. Treatment of menorrhagia associated with oral anticoagulation: efficacy of levonorgestrel releasing intrauterine device. Thromb Res 115 Suppl 1 (2005) 121-122 [abstract]
21. Kouides P., Phatak P., Sham R., Braggins L., Andrews C., and Howard F. The efficacy and safety of the levonorgestrel intrauterine device (Mirena) for bleeding disorder-related menorrhagia in an American cohort. Hemophilia 12 Suppl 2 (2006) 146 [abstract]
22. Mansour M.S.A., and Mansour D.J.A. The effectiveness of the levonorgestrel intrauterine system (LNG IUS) in the treatment of menorrhagia in a district clinic for abnormal uterine bleeding. Br J Obstet Gynaecol 105 Suppl (1998) 105 [abstract 323]
23. Nilsson C.G., Luukkainen T., Diaz J., et al. Clinical performance of a new levonorgestrel-releasing intrauterine device: a randomized comparison with a Nova-T-copper device. Contraception 25 (1982) 345-356
24. Barrington J.W., and Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 104 (1997) 614-616
25. Vercellini P., Frontino G., De Giorgi O., Aimi G., Zaina B., and Crosignani P.G. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 80 (2003) 305-309
26. Greer I.A., Lowe G.D., Walker J.J., and Forbes C.D. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol 98 (1991) 909-918
27. Gomez A., Lucia J.F., Perella M., and Aguilar C. Haemoperitoneum caused by haemorrhagic corpus luteum in a patient with Type 3 von Willebrand's disease. Hemophilia 4 (1998) 60-62
28. Bottini E., Pareti F.I., Mari D., Mannucci P.M., Muggiasca M.L., and Conti M. Prevention of haemoperitoneum during ovulation by oral contraceptives in women with Type III von Willebrand's disease and afibrinogenemia (case report). Haematologica 76 (1991) 431-433
29. Lockhat F.B., Emembolu J.O., and Konje J.C. The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum Reprod 19 (2004) 179-184
30. Petta C.A., Ferriani R.A., Abrao M.S., et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod 20 (2005) 1993-1998
31. Gardner F.J., Konje J.C., Abrams K.R., et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 356 9243 (2000) 1171-1177
32. Boon J., Scholton P.C., Oldenhave A., and Heints A.P. Continuous intrauterine compared with cyclic oral progestin administration in perimenopausal HRT. Maturitas 46 (2003) 69-77
33. Wollter-Svensson L.O., Stadberg E., Andersson K., Mattsson L.A., Odlind V., and Persson I. Intrauterine administration of levonorgestrel 5 and 10 microg/24 h in perimenopausal hormone replacement therapy. A randomised clinical study during one year. Acta Obstet Gynecol Scand 76 (1997) 449-554
34. Raudaskoski T., Tapanainen J., Tomas E., et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 109 (2002) 136-144
35. Vereide A.B., Arnes M., Straume B., Maltau J.M., and Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 91 (2003) 526-533
36. Wilemeersch D., and Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 188 (2003) 1297-1298
37. Montz F.J., Bristow R.E., Bovicelli A., Tomacruz R., and Kurman R.J. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 186 (2002) 651-657
38. Xiao B., Wu S.C., Chong J., Zeng T., Han L.H., and Luukkainen T. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril 79 (2003) 963-969
39. Silverberg S.G., Haukkamaa M., Arko H., Nilsson C.G., and Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 5 (1986) 235-241
40. Hurskainen R., Teperi J., Rissanen P., et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 291 (2004) 1456-1463
41. Pakarinen P., Suvisaari J., Luukkainen T., and Lahteenmaki P. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles. Fertil Steril 68 (1997) 59-64
42. Jarvela I., Tekay A., and Jouppila P. The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum Reprod 13 (1998) 3379-3383
43. Inki P., Hurskainen R., Palo P., et al. Comparison of ovarian cyst formation in women using the levonorgestrel-releasing intrauterine system vs. hysterectomy. Ultrasound Obstet Gynecol 20 (2002) 381-385
44. World Health Organization. Cardiovascular disease and use of oral and injectable progestogen only contraceptives and combine injectable contraceptives. Results of an international, multicenter, case control study. Contraception 57 (1998) 315-324
45. Vasilakis C., Jick H., and del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 354 (1999) 1610-1611
46. Nilsson C.G., Lahteenmaki P.L.A., Luukkainen T., and Robertson D.N. Sustained intrauterine release of levonorgestrel over five years. Fertil Steril 45 (1986) 805-807
47. Diaz S., Pavez M., Miranda P., Johansson E.D.B., and Croxatto H.B. Long-term follow-up of women treated with Norplant® implants. Contraception 35 (1987) 551-567
48. Kuhnz W., Al-Yacoub G., and Fuhrmeister A. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation. Contraception 46 (1992) 455-469
49. Weiner E., Victor A., and Johansson E.D.B. Plasma levels of d-norgestrel after oral administration. Contraception 14 (1976) 563-570
50. World Health Organization (WHO). Medical eligibility criteria for contraceptive use. 3rd ed (2004), WHO, Geneva, Switzerland